Clinical Trials
5 trialsNCT06506955 2026-05-28
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
NCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT05036681 2026-03-27
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04189445 2025-10-08
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting